Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 7/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21019437 | 0.90 | HTR2A (0.42) | MAOBHTR2AHTR2C | |
| SCHEMBL18503379 | 0.86 | HTR2A (0.42) | MAOBHTR2AHTR2C | |
| SCHEMBL20827828 | 0.84 | ESR2 (0.41) | HTR2AHTR2C | |
| SCHEMBL91857 | 0.83 | MAOB (0.39) | MAOBHTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8447276 | 0.82 | MAOB (0.40) | MAOBHTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL8447277 | 0.82 | MAOB (0.40) | MAOBHTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL22219356 | 0.82 | HTR2A (0.33) | MAOBHTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL16191373 | 0.81 | MAOB (0.54) | MAOBGPR84 | |
| SCHEMBL8448297 | 0.81 | MAOB (0.40) | MAOBHTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL8454671 | 0.81 | MAOB (0.40) | MAOBHTR2AHTR2CSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544365-B2 | Nematic liquid crystal composition | DIC CORPORATION (JP) | 2020-01-28 | — | — | US | disclosed |
| WO-2019184860-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | 江苏和成显示科技有限公司 | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544365-B2 | Nematic liquid crystal composition | DOCK5, CDKL5, NCS1 | MAOB 4804/4885HTR2A 4252/4885HTR2C 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.